Dyno Therapeutics, Inc. announced the launch of Dyno‑bn8, a next‑generation adeno‑associated virus (AAV) delivery vector optimized for both skeletal and cardiac muscle gene therapies. According to the company, non‑human primate studies showed that Dyno‑bn8 transduced approximately 81 % of skeletal muscle fibers and 20 % of cardiac cells at an intravenous dose of 5.2 × 10¹² vg/kg—a dose roughly 25 times lower than that used in comparable existing therapies.
The company asserts that Dyno‑bn8 achieves these improved delivery levels while simultaneously reducing off‑target uptake in the liver—a key safety concern with AAV vectors. Dyno states the capsid also demonstrated compatibility with human ortholog receptors and human muscle cell lines in vitro, as well as manufacturability at large scale using existing AAV9‑based production workflows.
Dyno‑bn8 is positioned as part of Dyno’s broader capsid portfolio—which includes vectors for ocular and central nervous system applications—and is available for licensing through Dyno’s Frontiers Program aimed at gene‑therapy developers.
While Dyno emphasizes the therapeutic potential of Dyno‑bn8, it is important to note that the data to date are preclinical and have not yet been disclosed in human trials. As always, further clinical validation will be required to confirm safety, effectiveness and manufacturability in the gene‑therapy context.
